Originally published as JCO Early Release 10.1200/JCO.2004.10.086 on March 15 2004
Journal of Clinical Oncology, Vol 22, No 8 (April 15), 2004: pp. 1454-1459
© 2004 American Society of Clinical Oncology.
Stage I and II Follicular Non-Hodgkins Lymphoma: Long-Term Follow-Up of No Initial Therapy
Ranjana Advani,
Saul A. Rosenberg,
Sandra J. Horning
From the Division of Oncology, Department of Medicine, Stanford University Medical Center, Stanford, CA
Address reprint requests to Ranjana Advani, MD, Division of Oncology, 875 Blake Wilber Dr, Stanford, CA 94305; e-mail: radvani{at}stanford.edu
PURPOSE: To analyze the outcome of no initial therapy in stage I and II follicular small-cleaved (FSC) and follicular mixed (FM) non-Hodgkins lymphoma (NHL) on overall survival, time to treatment, incidence and course of transformation, and cause of death.
PATIENTS AND METHODS: This was a retrospective analysis. Criteria for selection were patients with stage I and IIA FSC and FM (grades 1 and 2) NHL with therapy deferred for at least 3 months after diagnosis and a minimum follow-up of 1 year.
RESULTS: Forty-three patients were identified (11 stage I, 32 stage II), with a median age of 58 years. Reasons for no initial therapy included: physician choice (n = 20), large abdominal radiation field required (n = 10), advanced age (n = 7), concern for xerostomia (n = 4), or patient refusal (n = 2). At a median follow-up of 86 months, 27 patients (63%) had not been treated. The median time to treatment in the remaining 16 patients was 22 months. Four of 16 patients transformed to a higher-grade lymphoma. Nine patients diedsix due to progressive lymphoma. Estimated survivals at 5, 10, and 20 years were 97%, 85%, and 22%, respectively.
CONCLUSION: In selected stage I and II follicular NHL patients, deferred therapy is an acceptable approach, as more than half of our patients remained untreated at a median of 6 or more years, and survival was comparable to that seen in reports with immediate treatment.
Supported in part by National Institutes of Health grant No. CA34233.
Presented at the 8th International Conference on Malignant Lymphomas, Lugano, Switzerland, June 12-15, 2002.
Authors disclosures of potential conflicts of interest are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
G. Martinelli, G. Ryan, J. F. Seymour, L. Nassi, S. Steffanoni, A. Alietti, L. Calabrese, G. Pruneri, L. Santoro, M. Kuper-Hommel, et al.
Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group
Ann. Onc.,
July 1, 2009;
(2009)
mdp238v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Martin, A. Chadburn, P. Christos, K. Weil, R. R. Furman, J. Ruan, R. Elstrom, R. Niesvizky, S. Ely, M. DiLiberto, et al.
Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma
J. Clin. Oncol.,
March 10, 2009;
27(8):
1209 - 1213.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. W. Friedberg, M. D. Taylor, J. R. Cerhan, C. R. Flowers, H. Dillon, C. M. Farber, E. S. Rogers, J. D. Hainsworth, E. K. Wong, J. M. Vose, et al.
Follicular Lymphoma in the United States: First Report of the National LymphoCare Study
J. Clin. Oncol.,
March 10, 2009;
27(8):
1202 - 1208.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Bendandi
Aiming at a Curative Strategy for Follicular Lymphoma
CA Cancer J Clin,
September 1, 2008;
58(5):
305 - 317.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. A. Salles
Clinical Features, Prognosis and Treatment of Follicular Lymphoma
Hematology,
January 1, 2007;
2007(1):
216 - 225.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Venugopal and S. A. Gregory
Lymphoproliferative disorders
ASH Self-Assessment Program,
January 1, 2007;
2007(1):
265 - 297.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Oschlies, W. Klapper, M. Zimmermann, M. Krams, H.-H. Wacker, B. Burkhardt, L. Harder, R. Siebert, A. Reiter, and R. Parwaresch
Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial
Blood,
May 15, 2006;
107(10):
4047 - 4052.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Tanimoto, A. Kaneko, S. Suzuki, N. Sekiguchi, D. Maruyama, S. W. Kim, T. Watanabe, Y. Kobayashi, Y. Kagami, A. Maeshima, et al.
Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma
Ann. Onc.,
January 1, 2006;
17(1):
135 - 140.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Wundisch, C. Thiede, A. Morgner, A. Dempfle, A. Gunther, H. Liu, H. Ye, M.-Q. Du, T. D. Kim, E. Bayerdorffer, et al.
Long-Term Follow-Up of Gastric MALT Lymphoma After Helicobacter Pylori Eradication
J. Clin. Oncol.,
November 1, 2005;
23(31):
8018 - 8024.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. A. Lister
Improved Survival for Patients With Follicular Lymphoma
J. Clin. Oncol.,
August 1, 2005;
23(22):
4830 - 4831.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Bjorck, S. Ek, O. Landgren, M. Jerkeman, M. Ehinger, M. Bjorkholm, C. A. K. Borrebaeck, A. Porwit-MacDonald, and M. Nordenskjold
High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma
Blood,
April 1, 2005;
105(7):
2908 - 2915.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. N. Winter, R. D. Gascoyne, and K. Van Besien
Low-Grade Lymphoma
Hematology,
January 1, 2004;
2004(1):
203 - 220.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|